碳离子放疗联合笔束扫描治疗III期非小细胞肺癌的毒性、生存与预后因素
该研究纳入2016年12月至2023年6月接受笔束扫描碳离子放疗的III期非小细胞肺癌患者181例,相对生物效应加权剂量为77 Gy(范围69-83.6 Gy),分22次(范围19-24次)照射,96.1%的患者在碳离子放疗前后接受全身治疗。中位随访18.2个月,2年总生存率为64.2%,中位总生存期为37.1个月,碳离子放疗后免疫治疗是改善总生存、无远处转移生存和无进展生存的独立预后因素。
要点
- 碳离子放疗后免疫治疗是改善总生存、无远处转移生存和无进展生存的独立预后因素。
- 碳离子放疗剂量≤77 Gy组总生存优于更高剂量组(P = .047),但局部区域控制更差(P = .026)。
- 3级及以上晚期毒性多发生于碳离子放疗剂量≥79.2 Gy的患者(占72.7%)。
核心结论
- 笔束扫描碳离子放疗对局部晚期非小细胞肺癌有效,毒性可接受且总生存结果良好,尤其在剂量为69至77 Gy并联合碳离子放疗后免疫治疗时。
研究设计与样本
- 该研究为分析性研究,纳入2016年12月至2023年6月接受碳离子放疗的III期非小细胞肺癌患者181例。
- 碳离子放疗采用基于局部效应模型的生物剂量计算,相对生物效应加权剂量为77 Gy(范围69-83.6 Gy),分22次(范围19-24次)照射。
- 96.1%的患者在碳离子放疗前和/或后接受全身治疗,记录毒性和生存结局并进行统计分析。
主要发现
- 中位随访期为18.2个月。
- 1级、2级、3级和4级急性毒性分别见于62.4%、30.4%、2.8%和0.6%的患者,所有3级及以上急性毒性均为血液学毒性。
- 1级、2级、3级和4级晚期毒性分别见于40.3%、30.9%、4.4%和1.7%的患者,大多数(72.7%)3级及以上碳离子放疗所致晚期毒性见于碳离子放疗剂量≥79.2 Gy的患者。
- 中位总生存期和无进展生存期分别为37.1个月和16.7个月,2年局部区域控制率、总生存率、无进展生存率和无远处转移生存率分别为66.1%、64.2%、40.3%和49.5%。
- 碳离子放疗剂量≤77 Gy组总生存优于更高剂量组(P = .047),但局部区域控制更差(P = .026);碳离子放疗后免疫治疗是改善总生存、无远处转移生存和无进展生存的独立预后因素(P = .002、P < .001和P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the toxicities and survival outcomes associated with carbon ion radiation therapy (CIRT) using pencil beam scanning (PBS) technique and to assess the prognostic factors for patients with stage III non-small cell lung cancer (NSCLC) using a local effect model (LEM)-based biological dose calculation. METHODS AND MATERIALS: This analysis included patients with stage III NSCLC (n = 181) who received CIRT between December 2016 and June 2023. CIRT was administered at a relative biological effectiveness-weighted dose of 77 Gy (range, 69-83.6 Gy) in 22 fractions (Fx) (range, 19-24 Fx). Most patients (96.1%) underwent systemic therapy before and/or after CIRT. Toxicities and survival outcomes were recorded, and statistical analyses conducted. RESULTS: The median follow-up period was 18.2 months. Grade 1, 2, 3, and 4 acute toxicities were observed in 62.4%, 30.4%, 2.8%, and 0.6% of patients, respectively, with hematological toxicities accounting for all grade ≥ 3 acute toxicities. Grade 1, 2, 3, and 4 late toxicities occurred in 40.3%, 30.9%, 4.4%, and 1.7% of patients, respectively, with most grade ≥ 3 CIRT-induced late toxicities (72.7%) observed in patients receiving a CIRT dose ≥ 79.2 Gy. The median overall survival (OS) and progression-free survival (PFS) were 37.1 and 16.7 months, respectively. The 2-year locoregional control, OS, PFS, and distant metastasis-free survival rates were 66.1%, 64.2%, 40.3%, and 49.5%, respectively. Patients who received a CIRT dose ≤ 77 Gy had better OS (P = .047), but worse locoregional control compared with those who received higher doses (P = .026). Post-CIRT immunotherapy was an independent prognostic factor for improved OS, distant metastasis-free survival, and PFS (P = .002, P < .001, and P < .001, respectively). CONCLUSIONS: CIRT with pencil beam scanning was effective for locally advanced NSCLC, resulting in acceptable toxicities and promising OS outcomes, particularly with doses of 69 to 77 Gy and post-CIRT immunotherapy.
引用
- Ma N, Ming X, Chen J, et al. Carbon Ion Radiation Therapy with Pencil Beam Scanning for Stage III Non-Small Cell Lung Cancer: Toxicity Profiles, Survival Outcomes, and Prognostic Indicators. Int J Radiat Oncol Biol Phys. 2025. PMID: 39921110. doi:10.1016/j.ijrobp.2025.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。